I. Introduction: Beyond "Selling Molecules"
For much of the past decade, the dominant model for Chinese biopharma globalization was straightforward: develop a drug to a certain stage, license it to a multinational corporation for upfront and milestone payments, and let the MNC handle global development and commercialization. That model — often described as "selling molecules" — generated significant revenue but limited Chinese companies' participation in the long-term value of their own innovations.
In 2026, that model is being fundamentally restructured. Co-Co (co-development, co-commercialization) agreements, NewCo structures, and platform-level collaborations are emerging as the new standard. These arrangements allow Chinese companies to retain equity in their assets, participate in global commercialization, and share in the full value of their innovation — not just the upfront payment.
II. The Co-Co Model: Innovent × Pfizer
On May 29, 2026, Innovent Biologics and Pfizer announced a global strategic collaboration covering 12 early-stage and source-innovation oncology programs. The total deal value reached $10.5 billion, with an upfront payment of $650 million.
Key structural features:
| Feature | Detail |
|---|---|
| Programs covered | 12 early-stage oncology assets |
| Co-Co programs | 4 key projects with joint global development |
| Cost sharing | Joint development costs for Co-Co programs |
| Commercialization | Joint commercialization in U.S. and Europe with profit sharing |
| Asset types | ADCs with novel differentiated payloads, multi-specific antibodies |
This is not a traditional license. For the four Co-Co programs, Innovent and Pfizer will jointly develop the assets globally, jointly bear development costs, and jointly commercialize in the U.S. and Europe — sharing profits rather than receiving royalties.
The practical difference is substantial. In a traditional license, if a drug achieves $5 billion in annual sales, the Chinese licensor receives a royalty (typically 5–15%) on net sales. In a Co-Co arrangement, the Chinese company shares in the actual profit pool — potentially 50% of a much larger pie. The trade-off is that the Chinese company must co-invest in development, sharing both risk and reward.
III. Platform-Level Collaboration: Hengrui × BMS
On May 12, 2026, Hengrui Medicine and Bristol Myers Squibb announced a global strategic collaboration covering 13 early-stage programs across oncology, hematology, and immunology. The potential total deal value reached $15.2 billion, with BMS paying up to $950 million in upfront and near-term payments, including a $600 million upfront payment.
What distinguishes this deal:
- Breadth: 13 programs across three therapeutic areas — not a single-asset deal.
- Stage: All programs are early-stage, reflecting BMS's confidence in Hengrui's discovery engine.
- Structure: The agreement incorporates co-development and co-commercialization elements for select programs, allowing Hengrui to participate in global commercialization.
This deal represents a validation of Hengrui's R&D platform rather than a single molecule. BMS is effectively investing in Hengrui's ability to generate novel drug candidates — a "platform bet" rather than an "asset bet."
IV. The NewCo Model: Asset Corporatization
The NewCo model represents a third distinct approach. In this structure, a Chinese company transfers pipeline assets into a newly created independent entity, typically backed by Western venture capital and often led by an experienced management team. The Chinese company retains equity in the NewCo, creating the potential for value appreciation and long-term commercialization returns beyond traditional milestone payments.
2026 NewCo activity:
- As of June 25, 2026, at least 13 NewCo companies based on Asian asset licensing had been established in the U.S. and Europe, 9 of which involve Chinese company assets.
- Hansoh Pharmaceutical licensed its oral IL-23 inhibitor to U.S.-based Avere under a NewCo structure, with an upfront payment of $120 million and total deal value of $2.3 billion. Avere simultaneously announced a merger with Nasdaq-listed NextCure, achieving a backdoor listing.
- Laekna Therapeutics entered a NewCo agreement with Vasque Bio in June 2026, establishing an overseas entity around clinical-stage assets.
The NewCo model is particularly suited for assets that are scientifically promising but commercially uncertain. By housing them in a dedicated entity with focused management and dedicated capital, the Chinese parent company can preserve upside potential without diverting resources from its core pipeline.
V. "Systematic Globalization": The Full-Stack Approach
A fourth model — perhaps the most ambitious — is being pioneered by companies like Henlius. In September 2026, Henlius outlined a "systematic globalization" strategy that goes beyond any single deal structure. The company described a three-phase roadmap:
| Phase | Timeline | Objective |
|---|---|---|
| Phase 1 | 2026–2027 | Establish direct U.S. market access |
| Phase 2 | 2028–2030 | Expand into EU and other high-value markets |
| Phase 3 | 2030+ | Become a global biopharmaceutical leader (C-MNC) |
This approach emphasizes building internal capabilities across the full value chain: early-stage R&D, global clinical development, regulatory affairs in multiple jurisdictions, global manufacturing, and direct commercialization. Henlius has 10 products approved in over 60 countries, with four consecutive years of U.S. approvals (one in 2024, three in 2025, one expected in 2026).
The company's partnership with Sandoz covers up to 10 monoclonal antibody and ADC biosimilars, with Henlius receiving 40% of net sales or net profit from the first three products — corresponding to an originator market of approximately $10.77 billion.
VI. Comparison of Globalization Models
| Model | Structure | Chinese Company's Role | Typical Deal Size | Best Suited For |
|---|---|---|---|---|
| Traditional License | Out-license to MNC | Royalty recipient | $100M–$1B | Early-stage assets, resource-constrained companies |
| Co-Co | Joint development & commercialization | Co-developer, profit-sharer | $1B–$10B+ | Mid-to-late-stage assets with strong data |
| Platform Collaboration | Multi-asset platform deal | Discovery engine partner | $10B+ | Companies with proven discovery platforms |
| NewCo | Asset corporatization | Equity holder in new entity | $100M–$2B | Assets needing focused development |
| Systematic Globalization | Full-stack internal build | Global commercializer | N/A (internal investment) | Companies with scale and ambition |
VII. What This Means for International Patients
The evolution of Chinese pharma's globalization models has direct implications for treatment access:
- Faster global availability: Co-Co and platform deals typically accelerate global development timelines because both partners are incentivized to advance programs quickly.
- Quality validation: When BMS commits $950 million to a 13-program platform, or Pfizer commits $650 million upfront to 12 oncology assets, it reflects rigorous due diligence on Chinese innovation quality.
- Competitive pricing: Chinese-origin therapies commercialized through these models typically enter global markets at prices below comparable Western-developed drugs, while maintaining international quality standards.
- Expanded pipeline: As Chinese companies retain greater control over global commercialization, they have stronger incentives to develop therapies for indications that may be underserved by Western pharma — particularly cancers with high prevalence in Asia.
VIII. Conclusion
The shift from "selling molecules" to "co-building global franchises" represents a coming-of-age for China's biopharmaceutical industry. The 2026 deals — Innovent-Pfizer, Hengrui-BMS, and the growing NewCo ecosystem — demonstrate that Chinese companies are no longer content to be upstream suppliers of drug candidates. They are becoming full participants in the global pharmaceutical value chain. For patients worldwide, this means more therapies, from more sources, at more competitive prices.